INNATE PHARMA SA (IPHA): Price and Financial Metrics


INNATE PHARMA SA (IPHA): $2.91

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IPHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IPHA POWR Grades


  • IPHA scores best on the Sentiment dimension, with a Sentiment rank ahead of 78.85% of US stocks.
  • The strongest trend for IPHA is in Quality, which has been heading down over the past 69 days.
  • IPHA's current lowest rank is in the Momentum metric (where it is better than 4.13% of US stocks).

IPHA Stock Summary

  • Innate Pharma SA's stock had its IPO on October 18, 2019, making it an older stock than merely 6.71% of US equities in our set.
  • With a year-over-year growth in debt of 117.09%, Innate Pharma SA's debt growth rate surpasses 91.07% of about US stocks.
  • Revenue growth over the past 12 months for Innate Pharma SA comes in at -67.83%, a number that bests only 2.1% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are PZG, SONN, INFI, NVEC, and PULM.
  • IPHA's SEC filings can be seen here. And to visit Innate Pharma SA's official web site, go to www.innate-pharma.com.

IPHA Stock Price Chart Interactive Chart >

Price chart for IPHA

IPHA Price/Volume Stats

Current price $2.91 52-week high $11.95
Prev. close $2.91 52-week low $2.66
Day low $2.89 Volume 28,400
Day high $3.03 Avg. volume 25,267
50-day MA $3.08 Dividend yield N/A
200-day MA $4.33 Market Cap 232.01M

INNATE PHARMA SA (IPHA) Company Bio


Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.


IPHA Latest News Stream


Event/Time News Detail
Loading, please wait...

IPHA Latest Social Stream


Loading social stream, please wait...

View Full IPHA Social Stream

Latest IPHA News From Around the Web

Below are the latest news stories about Innate Pharma SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.

Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022

MARSEILLE, France, February 15, 2022--Number of shares and voting rights of Innate Pharma as of February 1, 2022

Yahoo | February 15, 2022

Innate Pharma to Participate in Upcoming Investor Conferences

MARSEILLE, France, February 04, 2022--Innate Pharma to participate in upcoming investor conferences

Yahoo | February 4, 2022

Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022

MARSEILLE, France, January 24, 2022--Number of shares and voting rights of Innate Pharma as of January 1, 2022

Yahoo | January 24, 2022

Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans

MARSEILLE, France, January 05, 2022--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans

Yahoo | January 5, 2022

Innate Pharma (NASDAQ:IPHA) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Innate Pharma (NASDAQ:IPHA) from a sell rating to a hold rating in a report published on Thursday morning, Zacks.com reports. According to Zacks, Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The companys commercial-stage product includes []

Transcript Daily | December 19, 2021

Read More 'IPHA' Stories Here

IPHA Price Returns

1-mo 3.56%
3-mo -14.41%
6-mo -39.38%
1-year -24.41%
3-year N/A
5-year N/A
YTD -36.18%
2021 11.49%
2020 -36.49%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5224 seconds.